Kairos Pharma (KAPA) Non Operating Income (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Non Operating Income came in at $34000.0 in Q2 2025, up 209.68% YoY from $10979.2 in Q2 2024, and up 750.0% on a QoQ basis from $4000.0 in Q1 2025.
Kairos Pharma (KAPA) Non Operating Income (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Non Operating Income data on file, last reported at $34000.0 in Q2 2025.
- Quarterly Non Operating Income rose 209.68% year-over-year to $34000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$160000.0 (down 32.23% YoY) and the FY2025 annual result came in at $125000.0, up 148.08% from the prior year.
- Non Operating Income climbed to $34000.0 in Q2 2025, from $4000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $466000.0 in Q4 2024 to a low of -$664000.0 in Q3 2024.
- A 3-year average of -$35125.0 and a median of -$27000.0 in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1706.9% in 2024, down 2556.0% in 2024.
- Tracing KAPA's Non Operating Income over 3 years: stood at -$29000.0 in 2023, then soared by 1706.9% to $466000.0 in 2024, then plunged by 92.7% to $34000.0 in 2025.
- The last three Non Operating Income figures came in at $34000.0 (Q2 2025), $4000.0 (Q1 2025), and $466000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 466,000.00 |
| Sep 30, 2024 | -664,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | -29,000.00 |
| Sep 30, 2023 | -25,000.00 |